US5981719A
(en)
|
1993-03-09 |
1999-11-09 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
US6090925A
(en)
|
1993-03-09 |
2000-07-18 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
US5766629A
(en)
|
1995-08-25 |
1998-06-16 |
Sangstat Medical Corporation |
Oral cyclosporin formulations
|
US6368586B1
(en)
|
1996-01-26 |
2002-04-09 |
Brown University Research Foundation |
Methods and compositions for enhancing the bioadhesive properties of polymers
|
US5985312A
(en)
*
|
1996-01-26 |
1999-11-16 |
Brown University Research Foundation |
Methods and compositions for enhancing the bioadhesive properties of polymers
|
US6120806A
(en)
*
|
1997-06-25 |
2000-09-19 |
Whitmire; David R. |
Oral formulations for controlled release of alcohol deterrents
|
FR2775435B1
(en)
*
|
1998-02-27 |
2000-05-26 |
Bioalliance Pharma |
NANOPARTICLES COMPRISING AT LEAST ONE POLYMER AND AT LEAST ONE COMPOUND CAPABLE OF COMPLEXING ONE OR MORE ACTIVE INGREDIENTS
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US20050085498A1
(en)
*
|
1998-05-28 |
2005-04-21 |
Byrd Edward A. |
Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
|
US6197340B1
(en)
*
|
1998-05-28 |
2001-03-06 |
Medical Research Institute |
Controlled release lipoic acid
|
US6905707B2
(en)
*
|
1998-05-28 |
2005-06-14 |
Medical Research Institute |
Controlled release arginine alpha ketoglutarate
|
US20040259895A1
(en)
*
|
1998-05-28 |
2004-12-23 |
Medical Research Institute |
Oral formulation of lipid soluble thiamine and lipoic acid
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
US8236352B2
(en)
*
|
1998-10-01 |
2012-08-07 |
Alkermes Pharma Ireland Limited |
Glipizide compositions
|
EP2266542A3
(en)
*
|
1998-10-01 |
2013-07-31 |
Elan Pharma International Limited |
Controlled release nanoparticulate compositions
|
US6984404B1
(en)
|
1998-11-18 |
2006-01-10 |
University Of Florida Research Foundation, Inc. |
Methods for preparing coated drug particles and pharmaceutical formulations thereof
|
ES2350454T3
(en)
*
|
1998-11-27 |
2011-01-24 |
Ucb Pharma S.A. |
COMPOSITIONS AND METHODS TO INCREASE THE MINERALIZATION OF THE BONE SUBSTANCE.
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
AU768535B2
(en)
|
1998-11-30 |
2003-12-18 |
Nanosphere, Inc. |
Nanoparticles with polymer shells
|
US20020054914A1
(en)
*
|
1999-02-03 |
2002-05-09 |
Tulin Morcol |
Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
|
US20040258763A1
(en)
*
|
1999-02-03 |
2004-12-23 |
Bell Steve J.D. |
Methods of manufacture and use of calcium phosphate particles containing allergens
|
CA2361421A1
(en)
|
1999-02-03 |
2000-08-10 |
Biosante Pharmaceuticals, Inc. |
Therapeutic calcium phosphate particles and methods of manufacture and use
|
US6410255B1
(en)
*
|
1999-05-05 |
2002-06-25 |
Aurora Biosciences Corporation |
Optical probes and assays
|
DE60043400D1
(en)
|
1999-05-14 |
2010-01-07 |
Nereus Pharmaceuticals Inc |
Interleukin-1 and tumor necrosis factor-alpha modulators, synthesis of these modulators and methods of applying these modulators
|
EP1754488A1
(en)
|
1999-05-24 |
2007-02-21 |
Introgen Therapeutics, Inc. |
Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
|
US6406745B1
(en)
|
1999-06-07 |
2002-06-18 |
Nanosphere, Inc. |
Methods for coating particles and particles produced thereby
|
US20040115134A1
(en)
*
|
1999-06-22 |
2004-06-17 |
Elan Pharma International Ltd. |
Novel nifedipine compositions
|
RU2155602C1
(en)
|
1999-11-30 |
2000-09-10 |
Оао "Куантум Сатис" |
Insulin-containing drug for oral using and method of its preparing
|
EP1259608B1
(en)
|
2000-02-23 |
2009-08-12 |
Life Technologies Corporation |
Modified fluorescent proteins
|
AU2001256156B2
(en)
|
2000-02-23 |
2006-01-05 |
Smithkline Beecham Biologicals S.A. |
Novel compounds
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
US6582713B2
(en)
|
2000-04-06 |
2003-06-24 |
Univ. Of Colorado - Colorado Springs |
Compositions and methods for promoting wound healing
|
US10293056B1
(en)
|
2000-05-24 |
2019-05-21 |
Board Of Regents, The University Of Texas System |
Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
|
CA2309575A1
(en)
*
|
2000-05-26 |
2001-11-26 |
James E. Guillet |
Internally cross-linked macromolecules
|
ATE526994T1
(en)
|
2000-06-20 |
2011-10-15 |
Corixa Corp |
MTB32A ANTIGEN FROM MYCOBACTERIA TUBERCULOSIS WITH INACTIVATED PROTEASE ACTIVITY AND FUSION PROTEINS THAT CONTAIN THE ANTIGEN
|
AR029540A1
(en)
|
2000-06-28 |
2003-07-02 |
Corixa Corp |
COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND THERAPY OF CA NCER DE PULMoN
|
US6602523B1
(en)
|
2000-08-17 |
2003-08-05 |
Technology Holding, Llc. |
Composite material and process for increasing bioavailability and activity of a beneficial agent
|
WO2002047610A2
(en)
*
|
2000-11-16 |
2002-06-20 |
The Regents Of The University Of California |
Marine actinomycete taxon for drug and fermentation product dicovery
|
JP2005500247A
(en)
*
|
2000-12-07 |
2005-01-06 |
ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム |
Treatment for human MDA-7
|
US20030072807A1
(en)
*
|
2000-12-22 |
2003-04-17 |
Wong Joseph Chung-Tak |
Solid particulate antifungal compositions for pharmaceutical use
|
US8067032B2
(en)
*
|
2000-12-22 |
2011-11-29 |
Baxter International Inc. |
Method for preparing submicron particles of antineoplastic agents
|
US9700866B2
(en)
*
|
2000-12-22 |
2017-07-11 |
Baxter International Inc. |
Surfactant systems for delivery of organic compounds
|
US20040256749A1
(en)
*
|
2000-12-22 |
2004-12-23 |
Mahesh Chaubal |
Process for production of essentially solvent-free small particles
|
US20040022862A1
(en)
*
|
2000-12-22 |
2004-02-05 |
Kipp James E. |
Method for preparing small particles
|
US20050048126A1
(en)
*
|
2000-12-22 |
2005-03-03 |
Barrett Rabinow |
Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
|
US6869617B2
(en)
*
|
2000-12-22 |
2005-03-22 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
US6977085B2
(en)
*
|
2000-12-22 |
2005-12-20 |
Baxter International Inc. |
Method for preparing submicron suspensions with polymorph control
|
US6951656B2
(en)
*
|
2000-12-22 |
2005-10-04 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
US20030096013A1
(en)
*
|
2000-12-22 |
2003-05-22 |
Jane Werling |
Preparation of submicron sized particles with polymorph control
|
US6884436B2
(en)
*
|
2000-12-22 |
2005-04-26 |
Baxter International Inc. |
Method for preparing submicron particle suspensions
|
US7193084B2
(en)
*
|
2000-12-22 |
2007-03-20 |
Baxter International Inc. |
Polymorphic form of itraconazole
|
JP2005504513A
(en)
|
2001-05-09 |
2005-02-17 |
コリクサ コーポレイション |
Compositions and methods for treatment and diagnosis of prostate cancer
|
US20030185892A1
(en)
*
|
2001-08-17 |
2003-10-02 |
Bell Steve J. D. |
Intraocular delivery compositions and methods
|
US20030095928A1
(en)
*
|
2001-09-19 |
2003-05-22 |
Elan Pharma International Limited |
Nanoparticulate insulin
|
US20060003012A9
(en)
*
|
2001-09-26 |
2006-01-05 |
Sean Brynjelsen |
Preparation of submicron solid particle suspensions by sonication of multiphase systems
|
BR0212833A
(en)
*
|
2001-09-26 |
2004-10-13 |
Baxter Int |
Preparation of submicron sized nanoparticles by dispersion and solvent or liquid phase removal
|
US7112340B2
(en)
*
|
2001-10-19 |
2006-09-26 |
Baxter International Inc. |
Compositions of and method for preparing stable particles in a frozen aqueous matrix
|
ES2405405T3
(en)
|
2001-12-17 |
2013-05-31 |
Corixa Corporation |
Compositions and procedures for the therapy and diagnosis of inflammatory bowel disease
|
CA2477780A1
(en)
*
|
2002-03-05 |
2003-09-18 |
Board Of Regents, The University Of Texas System |
Methods of enhancing immune induction involving mda-7
|
WO2003087763A2
(en)
|
2002-04-03 |
2003-10-23 |
Celltech R & D, Inc. |
Association of polymorphisms in the sost gene region with bone mineral density
|
US7332469B2
(en)
|
2002-04-05 |
2008-02-19 |
Board Of Regents The University Of Texas System |
Intrapleural single-chain urokinase alone or complexed to its soluble receptor protects against pleural adhesions
|
US7176232B2
(en)
|
2002-06-24 |
2007-02-13 |
The Regents Of The University Of California |
Salinosporamides and methods for use thereof
|
EP2269619A1
(en)
|
2002-08-12 |
2011-01-05 |
Jennerex Biotherapeutics ULC |
Methods and compositions concerning poxviruses and cancer
|
WO2004034970A2
(en)
*
|
2002-09-27 |
2004-04-29 |
Nereus Pharmaceuticals, Inc. |
Macrocyclic lactams
|
US20050051968A1
(en)
*
|
2002-11-13 |
2005-03-10 |
Froesel David William |
Washer toss game
|
AU2003298658A1
(en)
|
2002-11-15 |
2004-06-15 |
Idenix (Cayman) Limited |
2'-branched nucleosides and flaviviridae mutation
|
US7531191B2
(en)
*
|
2002-12-17 |
2009-05-12 |
Massachusetts Institute Of Technology |
Stimuli-responsive systems for controlled drug delivery
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
JP4838706B2
(en)
|
2003-01-06 |
2011-12-14 |
コリクサ コーポレイション |
Certain aminoalkyl glucosaminidophosphate compounds and their use
|
ATE513551T1
(en)
*
|
2003-01-24 |
2011-07-15 |
Flora Technology Inc |
COMPOSITIONS AND METHODS FOR RESTORING BACTERIAL FLORA
|
KR20060002793A
(en)
*
|
2003-03-03 |
2006-01-09 |
더 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
Methods and compositions involving mda-7
|
CN1835974A
(en)
|
2003-06-16 |
2006-09-20 |
细胞技术研究与发展公司 |
Antibodies specific for sclerostin and methods for increasing bone mineralization
|
CN1823070A
(en)
*
|
2003-06-20 |
2006-08-23 |
加利福尼亚大学董事会 |
Salinosporamides and methods for use thereof
|
NZ544588A
(en)
*
|
2003-06-20 |
2010-06-25 |
Nereus Pharmaceuticals Inc |
Use of salinosporamide A and analogs thereof for the treatment of cancer, inflammation and infectious diseases
|
CA2532228C
(en)
|
2003-07-16 |
2017-02-14 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
US7727752B2
(en)
|
2003-07-29 |
2010-06-01 |
Life Technologies Corporation |
Kinase and phosphatase assays
|
EP1525890A1
(en)
|
2003-10-02 |
2005-04-27 |
Complex Biosystems GmbH |
Protein-Proteophore complexes
|
AU2004285468B2
(en)
|
2003-10-22 |
2011-02-24 |
Fred Hutchinson Cancer Research Center |
Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
|
US8034790B2
(en)
*
|
2003-12-01 |
2011-10-11 |
Introgen Therapeutics |
Use of MDA-7 to inhibit pathogenic infectious organisms
|
KR20060132698A
(en)
*
|
2004-01-23 |
2006-12-21 |
니리어스 파마슈티컬즈, 인코퍼레이션 |
Bis-indole pyrroles useful as antimicrobials agents
|
BRPI0507680A
(en)
*
|
2004-02-13 |
2007-07-17 |
Nod Pharmaceuticals Inc |
therapeutic calcium phosphate particles and methods of manufacture and use thereof
|
US20070281041A1
(en)
*
|
2004-03-02 |
2007-12-06 |
Introgen Therapeutics, Inc. |
Compositions and Methods Involving MDA-7 for the Treatment of Cancer
|
EP2266988A1
(en)
*
|
2004-04-30 |
2010-12-29 |
Nereus Pharmaceuticals, Inc. |
[3.2.0] Heterocyclic compounds and methods of using the same
|
US7579371B2
(en)
|
2004-04-30 |
2009-08-25 |
Nereus Pharmaceuticals, Inc. |
Methods of using [3.2.0] heterocyclic compounds and analogs thereof
|
WO2006031264A2
(en)
|
2004-05-25 |
2006-03-23 |
Oregon Health And Science University |
Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors
|
WO2006004774A2
(en)
*
|
2004-06-28 |
2006-01-12 |
Stanford University |
Laulimalide analogues as therapeutic agents
|
FR2872703B1
(en)
*
|
2004-07-07 |
2006-10-06 |
Ethypharm Sa |
COMPOSITE POLYMERIC NANOPARTICLES
|
CN1733313A
(en)
*
|
2004-08-11 |
2006-02-15 |
张阳德 |
Process for preparing poly n-butyl cyan acrylate nanometer particle
|
CN1732962A
(en)
*
|
2004-08-11 |
2006-02-15 |
张阳德 |
Process for preparing nanometer particle of adriacin-PACA-PBCA
|
WO2006124047A2
(en)
*
|
2004-08-13 |
2006-11-23 |
Emisphere Technologies, Inc. |
Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
|
AU2005290238A1
(en)
|
2004-09-18 |
2006-04-06 |
Department Of Veterans Affairs |
Therapeutic agents trageting the NCCa-ATP channel and methods of use thereof
|
ATE487484T1
(en)
|
2004-09-18 |
2010-11-15 |
Univ Maryland |
THERAPEUTIC AGENTS FOR TARGETING THE NC CA ATP CHANNEL AND METHOD OF USE THEREOF
|
US7282194B2
(en)
*
|
2004-10-05 |
2007-10-16 |
Gp Medical, Inc. |
Nanoparticles for protein drug delivery
|
EP1811941A4
(en)
|
2004-11-01 |
2008-09-10 |
Biosante Pharmaceuticals Inc |
Therapeutic calcium phosphate particles iin use for aesthetic or cosmetic medicine, and methods of manufacture and use
|
NZ555439A
(en)
|
2004-12-03 |
2010-12-24 |
Dana Farber Cancer Inst Inc |
Use of salinosporamide A for treating neoplastic diseases which are resistant to the chemotherapeutic agents bortezomib, dexamethasone, doxorubicin or thalidomide
|
CN101166539B
(en)
*
|
2005-02-08 |
2012-01-04 |
得克萨斯大学体系董事会 |
Compositions and methods involving MDA-7 for the treatment of cancer
|
CA2597065C
(en)
|
2005-02-08 |
2014-10-14 |
Research Development Foundation |
Compositions and methods related to soluble g-protein coupled receptors (sgpcrs)
|
ES2259914B1
(en)
*
|
2005-03-14 |
2007-06-16 |
Advanced In Vitro Cell Technologies, S.L. |
NANOPARTICULAS OF QUITOSANO AND POLYETHYLENE GLYCOL AS A SYSTEM OF ADMINISTRATION OF BIOLOGICALLY ACTIVE MOLECULES.
|
AU2006229968A1
(en)
|
2005-03-31 |
2006-10-05 |
Corixa Corporation |
Vaccines against Chlamydial infection
|
EP3339348B1
(en)
|
2005-04-22 |
2019-12-04 |
Université de Genève |
Polylactide compositions and uses thereof
|
ITMI20050739A1
(en)
*
|
2005-04-22 |
2006-10-23 |
Effebi Spa |
VALVE-ACTUATOR CONNECTION PLATE
|
KR20150036658A
(en)
|
2005-04-29 |
2015-04-07 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
Novel method for preventing or treating m tuberculosis infection
|
US7592429B2
(en)
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
EP1906973A2
(en)
*
|
2005-06-14 |
2008-04-09 |
Baxter International Inc. |
Pharmaceutical formulations for minimizing drug-drug interactions
|
US20060280787A1
(en)
*
|
2005-06-14 |
2006-12-14 |
Baxter International Inc. |
Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
|
US7893299B2
(en)
|
2005-07-21 |
2011-02-22 |
Nereus Pharmaceuticals, Inc. |
Interleukin-1 and tumor necrosis factor-αmodulators; syntheses of such modulators and methods of using such modulators
|
WO2007016597A2
(en)
*
|
2005-07-29 |
2007-02-08 |
The Regents Of The University Of California |
Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
|
KR20080047395A
(en)
|
2005-08-25 |
2008-05-28 |
다이호야쿠힌고교 가부시키가이샤 |
Biodegradable nanoparticle having t-cell recognizable epitope peptide immobilized thereon or encapsulated therein
|
JP2009507853A
(en)
*
|
2005-09-07 |
2009-02-26 |
ジェンネレックス インコーポレイティッド |
Systemic treatment of metastatic and / or systemic disseminated cancer using GM-CSF expressing poxvirus
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
EP2395012B8
(en)
|
2005-11-02 |
2018-06-06 |
Arbutus Biopharma Corporation |
Modified siRNA molecules and uses thereof
|
KR20080080119A
(en)
*
|
2005-11-15 |
2008-09-02 |
백스터 인터내셔널 인코포레이티드 |
Compositions of lipoxygenase inhibitors
|
EP1956910B1
(en)
|
2005-11-23 |
2014-09-17 |
The Board of Regents of The University of Texas System |
Oncogenic ras-specific cytotoxic compound and methods of use thereof
|
WO2007062230A2
(en)
|
2005-11-28 |
2007-05-31 |
Gtx, Inc. |
Nuclear receptor binding agents
|
AU2007239095B2
(en)
|
2006-01-09 |
2012-05-03 |
The Regents Of The University Of California |
Immunostimulatory combinations for vaccine adjuvants
|
WO2007092944A2
(en)
*
|
2006-02-08 |
2007-08-16 |
Introgen Therapeutics, Inc. |
Compositions and methods involving gene therapy and proteasome modulation
|
EP1876188A1
(en)
*
|
2006-07-04 |
2008-01-09 |
NanoDel Technologies GmbH |
Two step miniemulsion process
|
CL2007002567A1
(en)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
ISOLATED PROTEINS FROM LINK TO ACTIVINE TO HUMAN.
|
US8097419B2
(en)
|
2006-09-12 |
2012-01-17 |
Longhorn Vaccines & Diagnostics Llc |
Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
|
US9481912B2
(en)
|
2006-09-12 |
2016-11-01 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
|
US8652782B2
(en)
|
2006-09-12 |
2014-02-18 |
Longhorn Vaccines & Diagnostics, Llc |
Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
|
US8080645B2
(en)
|
2007-10-01 |
2011-12-20 |
Longhorn Vaccines & Diagnostics Llc |
Biological specimen collection/transport compositions and methods
|
ES2551892T3
(en)
|
2006-09-15 |
2015-11-24 |
Ottawa Health Research Institute |
Oncolytic rhabdovirus
|
WO2008036776A2
(en)
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
|
US8466154B2
(en)
|
2006-10-27 |
2013-06-18 |
The Board Of Regents Of The University Of Texas System |
Methods and compositions related to wrapping of dehydrons
|
WO2008133722A2
(en)
*
|
2006-11-10 |
2008-11-06 |
Ucb Pharma S.A. |
Anti human sclerostin antibodies
|
US20100036091A1
(en)
*
|
2006-11-10 |
2010-02-11 |
Amgen Inc. |
Antibody-based diagnostics and therapeutics
|
US8715653B2
(en)
|
2006-11-21 |
2014-05-06 |
The Regents Of The University Of California |
Modulation of Rhamm (CD168) for selective adipose tissue development
|
US20080138418A1
(en)
*
|
2006-12-07 |
2008-06-12 |
Tong Shen Enterprise Co., Ltd. |
Nanoparticles composed of alkyl-cyanoacrylate polymers
|
CA2674949A1
(en)
|
2007-01-12 |
2008-07-24 |
J. Marc Simard |
Targeting ncca-atp channel for organ protection following ischemic episode
|
US8679539B2
(en)
*
|
2007-01-31 |
2014-03-25 |
Tong Shen Enterprise Co., Ltd. |
Drug-loaded poly (alkyl-cyanoacrylate) nanoparticles and process for the preparation thereof
|
US7824698B2
(en)
*
|
2007-02-02 |
2010-11-02 |
Nereus Pharmaceuticals, Inc. |
Lyophilized formulations of Salinosporamide A
|
WO2008097835A2
(en)
|
2007-02-02 |
2008-08-14 |
Baylor College Of Medicine |
Compositions and methods for the treatment of metabolic disorders
|
US20100092469A1
(en)
|
2007-02-09 |
2010-04-15 |
Simard J Marc |
Antagonists of a non-selective cation channel in neural cells
|
KR20080084528A
(en)
|
2007-03-15 |
2008-09-19 |
제네렉스 바이오테라퓨틱스 인크. |
Oncolytic vaccinia virus cancer therapy
|
DK2136836T3
(en)
*
|
2007-04-04 |
2017-04-10 |
Infectious Disease Res Inst |
Immunogenic compositions with mycobacterium tuberculosis polypeptides and fusions thereof
|
US9725485B2
(en)
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
PT2191001T
(en)
|
2007-04-09 |
2016-09-23 |
Univ Florida |
Raav vector compositions having tyrosine-modified capsid proteins and methods for use
|
US8722736B2
(en)
|
2007-05-22 |
2014-05-13 |
Baxter International Inc. |
Multi-dose concentrate esmolol with benzyl alcohol
|
US8426467B2
(en)
|
2007-05-22 |
2013-04-23 |
Baxter International Inc. |
Colored esmolol concentrate
|
SI2152663T1
(en)
|
2007-06-04 |
2014-08-29 |
Ben Gurion University Of The Negev Research And Development Authority |
Tri-aryl compounds and compositions comprising the same
|
EP2167107B1
(en)
|
2007-06-22 |
2016-12-14 |
University of Maryland, Baltimore |
Inhibitors of ncca-atp channels for therapy
|
US20090017167A1
(en)
*
|
2007-07-11 |
2009-01-15 |
Herbalife International Inc. |
Mixture and beverage made therefrom for protecting cellular hydration
|
US11041215B2
(en)
|
2007-08-24 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
PCR ready compositions and methods for detecting and identifying nucleic acid sequences
|
US9683256B2
(en)
|
2007-10-01 |
2017-06-20 |
Longhorn Vaccines And Diagnostics, Llc |
Biological specimen collection and transport system
|
US10004799B2
(en)
|
2007-08-27 |
2018-06-26 |
Longhorn Vaccines And Diagnostics, Llc |
Composite antigenic sequences and vaccines
|
RU2468034C2
(en)
|
2007-08-27 |
2012-11-27 |
ЛОНГХОРН ВЭКСИНС ЭНД ДИАГНОСТИКС ЭлЭлСи |
Immunogenic compositions and methods
|
CL2008002775A1
(en)
|
2007-09-17 |
2008-11-07 |
Amgen Inc |
Use of a sclerostin binding agent to inhibit bone resorption.
|
AU2008343745B2
(en)
|
2007-10-01 |
2012-05-10 |
Longhorn Vaccines & Diagnostics Llc |
Biological specimen collection and transport system and methods of use
|
US11041216B2
(en)
|
2007-10-01 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
|
US8394816B2
(en)
*
|
2007-12-07 |
2013-03-12 |
Irene Ghobrial |
Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
|
CN101896201A
(en)
|
2007-12-14 |
2010-11-24 |
安进公司 |
Method for treating bone fracture with anti-sclerostin antibodies
|
AU2008342535B2
(en)
|
2007-12-27 |
2015-02-05 |
Arbutus Biopharma Corporation |
Silencing of polo-like kinase expression using interfering RNA
|
US20100285140A1
(en)
*
|
2007-12-27 |
2010-11-11 |
Shoichi Shirotake |
Antimicrobial agent for gram-positive bacteria
|
AU2009236219B8
(en)
|
2008-04-15 |
2015-06-25 |
Arbutus Biopharma Corporation |
Silencing of CSN5 gene expression using interfering RNA
|
WO2009127060A1
(en)
|
2008-04-15 |
2009-10-22 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for nucleic acid delivery
|
WO2009137807A2
(en)
|
2008-05-08 |
2009-11-12 |
Asuragen, Inc. |
Compositions and methods related to mirna modulation of neovascularization or angiogenesis
|
BRPI0908686B8
(en)
*
|
2008-05-09 |
2021-05-25 |
South Dakota State Univ |
production method of non-immunogenic nanoparticles, therapeutically active non-immunogenic nanoparticle, therapeutic composition, use of a non-immunogenic nanoparticle and kit for the production of non-immunogenic nanoparticles
|
JP2011519975A
(en)
*
|
2008-05-12 |
2011-07-14 |
ネレアス ファーマシューティカルズ インコーポレイテッド |
Salinosporamide derivatives as proteasome inhibitors
|
EP2310498A1
(en)
|
2008-06-26 |
2011-04-20 |
Atyr Pharma, Inc. |
Compositions and methods comprising glycyl-trna synthetases having non-canonical biological activities
|
EP2326318A4
(en)
|
2008-09-16 |
2012-05-23 |
Univ Maryland |
Sur1 inhibitors for therapy
|
US8765817B1
(en)
|
2008-12-03 |
2014-07-01 |
Arrowhead Center, Inc. |
Selective inhibitors of EG5 motors and methods of use
|
US8349899B1
(en)
|
2008-12-03 |
2013-01-08 |
Arrowhead Center, Inc. |
Selective inhibitors of EG5 motors and methods of use
|
WO2010099477A2
(en)
|
2009-02-27 |
2010-09-02 |
Atyr Pharma, Inc. |
Polypeptide structural motifs associated with cell signaling activity
|
CN107574157A
(en)
|
2009-03-16 |
2018-01-12 |
盘古生物制药有限公司 |
Include the composition and method of the Histidyl-tRNA-synthetase splicing variants with non-classical bioactivity
|
US20100310576A1
(en)
|
2009-03-31 |
2010-12-09 |
Adams Ryan A |
COMPOSITIONS AND METHODS COMPRISING ASPARTYL-tRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES
|
EP3141561B1
(en)
|
2009-04-24 |
2018-09-12 |
Vanderbilt University |
Anti-tgf-beta induction of bone growth
|
WO2010135714A2
(en)
|
2009-05-22 |
2010-11-25 |
The Methodist Hospital Research Institute |
Methods for modulating adipocyte expression using microrna compositions
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
CA2767127A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for delivery of therapeutic agents to solid tumors
|
US8716464B2
(en)
|
2009-07-20 |
2014-05-06 |
Thomas W. Geisbert |
Compositions and methods for silencing Ebola virus gene expression
|
US9078865B2
(en)
|
2009-07-24 |
2015-07-14 |
Baylor College Of Medicine |
Methods of modulation of branched chain acids and uses thereof
|
WO2011025905A1
(en)
|
2009-08-28 |
2011-03-03 |
Research Development Foundation |
Urocortin 2 analogs and uses thereof
|
BR112012005774B8
(en)
|
2009-09-14 |
2023-02-14 |
Jennerex Inc |
use of an anti-angiogenic kinase inhibitor in cancer treatment
|
US9222086B2
(en)
|
2009-09-23 |
2015-12-29 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
MX337062B
(en)
|
2009-12-10 |
2016-02-11 |
Ottawa Hospital Res Inst |
Oncolytic rhabdovirus.
|
US9127268B2
(en)
|
2009-12-11 |
2015-09-08 |
Atyr Pharma, Inc. |
Aminoacyl tRNA synthetases for modulating inflammation
|
US20110150885A1
(en)
|
2009-12-11 |
2011-06-23 |
Atyr Pharma, Inc. |
Aminoacyl trna synthetases for modulating hematopoiesis
|
TW201132353A
(en)
|
2009-12-18 |
2011-10-01 |
Amgen Inc |
WISE binding agents and epitopes
|
DK2528621T3
(en)
|
2010-01-27 |
2017-01-02 |
Glaxosmithkline Biologicals Sa |
Modified tuberculosis antigens
|
CA3049237A1
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
PL2560624T3
(en)
|
2010-04-23 |
2019-01-31 |
Kempharm, Inc. |
Therapeutic formulation for reduced drug side effects
|
EP2561075B1
(en)
|
2010-04-23 |
2018-06-27 |
University of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
PT2561067T
(en)
|
2010-04-23 |
2019-02-04 |
Univ Florida |
Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1)
|
WO2011139714A2
(en)
|
2010-04-26 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
|
CN103096911B
(en)
|
2010-04-27 |
2018-05-29 |
Atyr 医药公司 |
Treatment relevant with the protein fragments of Isoleucyl-tRNA synthetase, diagnosis and the innovation of antibody compositions are found
|
JP6008837B2
(en)
|
2010-04-28 |
2016-10-19 |
エータイアー ファーマ, インコーポレイテッド |
Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of alanyl tRNA synthetase
|
EP2563912B1
(en)
|
2010-04-29 |
2018-09-05 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
|
CN103118693B
(en)
|
2010-04-29 |
2017-05-03 |
Atyr 医药公司 |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases
|
US9034321B2
(en)
|
2010-05-03 |
2015-05-19 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
|
WO2011139986A2
(en)
|
2010-05-03 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
|
CA2797978C
(en)
|
2010-05-03 |
2019-12-03 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
|
CA2798139C
(en)
|
2010-05-04 |
2019-09-24 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
|
US20130123338A1
(en)
|
2010-05-12 |
2013-05-16 |
Protiva Biotherapeutics, Inc. |
Novel cationic lipids and methods of use thereof
|
US10077232B2
(en)
|
2010-05-12 |
2018-09-18 |
Arbutus Biopharma Corporation |
Cyclic cationic lipids and methods of use
|
RS56210B1
(en)
|
2010-05-14 |
2017-11-30 |
Amgen Inc |
High concentration antibody formulations
|
JP6396656B2
(en)
|
2010-05-14 |
2018-09-26 |
エータイアー ファーマ, インコーポレイテッド |
Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of phenylalanyl βtRNA synthetase
|
JP6027965B2
(en)
|
2010-05-17 |
2016-11-16 |
エータイアー ファーマ, インコーポレイテッド |
Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of leucyl-tRNA synthetase
|
EP2575856B1
(en)
|
2010-05-27 |
2017-08-16 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
|
US8962560B2
(en)
|
2010-06-01 |
2015-02-24 |
Atyr Pharma Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Lysyl-tRNA synthetases
|
JP6116479B2
(en)
|
2010-07-12 |
2017-04-19 |
エータイアー ファーマ, インコーポレイテッド |
Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of glycyl-tRNA synthetase
|
EP3192880B1
(en)
|
2010-08-18 |
2019-10-09 |
Fred Hutchinson Cancer Research Center |
Nucleic acid agents for use in treating facioscapulohumeral dystrophy (fshd)
|
CN103108650A
(en)
|
2010-08-25 |
2013-05-15 |
Atyr医药公司 |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
|
WO2012057904A1
(en)
|
2010-10-27 |
2012-05-03 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
ES2859673T3
(en)
|
2010-11-08 |
2021-10-04 |
Infectious Disease Res Inst |
Vaccines comprising nonspecific nucleoside hydrolase polypeptides and sterol 24-c-methyltransferase (SMT) for the treatment and diagnosis of leishmaniasis
|
CN103429258B
(en)
|
2011-01-04 |
2016-03-09 |
新罗杰公司 |
By use oncolytic vaccinia virus generate for tumor antigen antibody and generate tumour-specific CDC
|
BR112013017711A2
(en)
|
2011-01-11 |
2016-08-23 |
Fate Therapeutics Inc |
wnt novel compositions and therapeutic uses of such compositions
|
WO2012103328A1
(en)
|
2011-01-26 |
2012-08-02 |
The Methodist Hospital Research Institute |
Labeled, non- peptidic multivalent integrin alpha -v - beta - 3 antagonists, compositions containing them and their use
|
US9222085B2
(en)
|
2011-02-03 |
2015-12-29 |
Mirna Therapeutics, Inc. |
Synthetic mimics of MIR-124
|
EP2670850B1
(en)
|
2011-02-03 |
2016-10-26 |
Mirna Therapeutics, Inc. |
Synthetic mimics of mir-34
|
US8986739B2
(en)
|
2011-02-28 |
2015-03-24 |
Nicholas V. Perricone |
Treatment of urinary incontinence using nitrone spin traps
|
EP2681242B1
(en)
|
2011-03-01 |
2018-01-24 |
Amgen Inc. |
Sclerostin and dkk-1 bispecific binding agents
|
CN103517920B
(en)
|
2011-03-25 |
2018-04-17 |
安进公司 |
Anti- hardened proteins (SCLEROSTIN) antibody crystals and its preparation
|
AU2012233439A1
(en)
|
2011-03-31 |
2013-11-14 |
Nanocame Co., Ltd. |
Novel preparation technique for higher-order structure that exhibits anti-cellular effect
|
RS57877B1
(en)
|
2011-04-19 |
2018-12-31 |
Amgen Inc |
Method for treating osteoporosis
|
ES2627529T3
(en)
|
2011-06-08 |
2017-07-28 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Compositions for glioblastoma treatment
|
RU2014100160A
(en)
|
2011-06-10 |
2015-07-20 |
Блуберд Байо, Инк. |
VECTORS OF GENE THERAPY OF ADRENOLEUIC DYSTROPHY AND ADRENOMYELONEUROPATHY
|
US20150030586A1
(en)
|
2011-06-21 |
2015-01-29 |
Sarah Ellen Warren |
Compositions and methods for the therapy and diagnosis of cancer
|
DK2734634T3
(en)
|
2011-07-22 |
2019-10-21 |
Univ Chicago |
IGF-1 FOR USE FOR THE TREATMENT OF Migraine
|
MX355816B
(en)
|
2011-08-04 |
2018-05-02 |
Amgen Inc |
Method for treating bone gap defects.
|
US9655905B2
(en)
|
2011-09-14 |
2017-05-23 |
King Abdullah University Of Science And Technology |
Treatment of sickle cell disease
|
WO2013041969A2
(en)
|
2011-09-21 |
2013-03-28 |
King Abdullah University Of Science And Technology |
Didemnin biosynthetic gene cluster in tistrella mobilis
|
WO2013043196A1
(en)
|
2011-09-23 |
2013-03-28 |
Bluebird Bio, Inc. |
Improved gene therapy methods
|
WO2013095736A2
(en)
|
2011-09-27 |
2013-06-27 |
The Methodist Hospital Research Institute |
Gold-in-silicon nanoassembly for thermal therapy and methods of use
|
SG11201401077PA
(en)
|
2011-09-30 |
2014-04-28 |
Bluebird Bio Inc |
Compounds for improved viral transduction
|
WO2013059676A1
(en)
|
2011-10-21 |
2013-04-25 |
Subhash Desai |
Compositions for reduction of side effects
|
WO2013151584A1
(en)
|
2011-10-31 |
2013-10-10 |
The Methodist Hospital Research Institute |
Compound comprising a mao targeting/ seeker moiety for treating human gliomas
|
CN107880101B
(en)
|
2011-11-11 |
2021-12-21 |
弗雷德哈钦森癌症研究中心 |
T cell immunotherapy targeting cyclin A1 against cancer
|
CN104185420B
(en)
|
2011-11-30 |
2017-06-09 |
埃默里大学 |
Antiviral JAK inhibitor for treating or preventing retrovirus and other virus infection
|
WO2013086433A1
(en)
|
2011-12-07 |
2013-06-13 |
The Methodist Hospital Research Institute |
Sirna compositions and methods for inhibiting gene expression in tumor initiating cells of breast cancer
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
IN2014CN04634A
(en)
|
2011-12-28 |
2015-09-18 |
Amgen Inc |
|
EP2805617A4
(en)
*
|
2012-01-19 |
2015-08-12 |
Shoichi Shirotake |
Antibacterial agent against plant disease-causing bacteria
|
EP3494989A1
(en)
|
2012-01-26 |
2019-06-12 |
Longhorn Vaccines and Diagnostics, LLC |
Composite antigenic sequences and vaccines
|
US20150024037A1
(en)
|
2012-02-16 |
2015-01-22 |
The University Of Toledo |
Xenoantigen-Displaying Anti-Cancer Vaccines and Method of Making
|
RS58077B1
(en)
|
2012-02-24 |
2019-02-28 |
Arbutus Biopharma Corp |
Trialkyl cationic lipids and methods of use thereof
|
AR092821A1
(en)
|
2012-04-20 |
2015-05-06 |
Sucampo Ag |
CONJUGATE OF GRASO-POLYMER ACID DERIVATIVE
|
KR20150010953A
(en)
*
|
2012-05-16 |
2015-01-29 |
글락소 그룹 리미티드 |
Polypeptide loaded poca nanoparticles for oral administration
|
US10307490B2
(en)
|
2012-05-23 |
2019-06-04 |
The Ohio State University |
Lipid nanoparticle compositions for antisense oligonucleotides delivery
|
WO2014006100A1
(en)
|
2012-07-05 |
2014-01-09 |
Ucb Pharma S.A. |
Treatment for bone diseases
|
RU2659149C2
(en)
|
2012-08-03 |
2018-06-28 |
Инфекшес Дизиз Рисерч Инститьют |
Compositions and methods for treating active mycobacterium tuberculosis infection
|
EP2931300A1
(en)
*
|
2012-08-14 |
2015-10-21 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
US20150224176A1
(en)
*
|
2012-08-14 |
2015-08-13 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
UY35148A
(en)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
HETERODIMERIC IMMUNOGLOBULINS
|
SG10201706148WA
(en)
|
2013-02-01 |
2017-08-30 |
Santa Maria Biotherapeutics Inc |
Administration of an anti-activin-a compound to a subject
|
US10363293B2
(en)
|
2013-02-21 |
2019-07-30 |
Turnstone Limited Partnership |
Vaccine composition
|
WO2014160339A1
(en)
|
2013-03-13 |
2014-10-02 |
Board Of Regents, The University Of Texas System |
Compounds for treating inflammatory and hyperproliferative diseases
|
EP2978447B1
(en)
|
2013-03-28 |
2019-05-08 |
Infectious Disease Research Institute |
Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
|
US10006049B2
(en)
|
2013-05-16 |
2018-06-26 |
University Of Florida Research Foundation, Incorporated |
Hairpin mRNA elements and methods for the regulation of protein translation
|
CA2919226A1
(en)
|
2013-07-23 |
2015-01-29 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for delivering messenger rna
|
JP6657101B2
(en)
|
2013-11-05 |
2020-03-04 |
ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ |
Compounds for the treatment of diabetes and disease complications resulting therefrom
|
NZ759287A
(en)
|
2013-12-02 |
2022-10-28 |
Baylor College Medicine |
Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose
|
US10351644B2
(en)
|
2014-02-27 |
2019-07-16 |
Shoichi Shirotake |
Antiviral drug
|
US10472334B2
(en)
|
2014-03-14 |
2019-11-12 |
The University Of North Carolina At Chapel Hill |
Small molecules for inhibiting male fertility
|
SG11201607795UA
(en)
|
2014-04-08 |
2016-10-28 |
Methodist Hospital |
Inos-inhibitory compositions and their use as breast cancer therapeutics
|
US9693994B2
(en)
|
2014-04-09 |
2017-07-04 |
Research Development Foundation |
Class IIa HDAC inhibitors for the treatment of infection
|
WO2015164786A1
(en)
|
2014-04-25 |
2015-10-29 |
University Of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
US20170137505A1
(en)
|
2014-06-20 |
2017-05-18 |
Aveo Pharmaceuticals, Inc. |
Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
|
AU2015276800B2
(en)
|
2014-06-20 |
2021-03-04 |
Aveo Pharmaceuticals, Inc. |
Treatment of chronic kidney disease and other renal dysfunction using a GDF15 modulator
|
WO2016025202A1
(en)
|
2014-08-14 |
2016-02-18 |
The Regents Of The University Of Colorado |
Antibody-sirna conjugates and uses therefor
|
CA2959522C
(en)
|
2014-09-01 |
2021-09-07 |
Academia Sinica |
Animal model of longevity and related methods for increasing longevity and inhibiting tumorigenesis
|
EP3628640B1
(en)
|
2014-09-02 |
2023-08-09 |
Hub Therapeutics |
Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment
|
KR102500531B1
(en)
|
2014-09-04 |
2023-02-17 |
메모리얼 슬로안 케터링 캔서 센터 |
Globin gene therapy for treating hemoglobinopathies
|
US20170306008A1
(en)
|
2014-09-25 |
2017-10-26 |
Aveo Pharmaceuticals, Inc. |
Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
|
US10415037B2
(en)
|
2014-10-02 |
2019-09-17 |
Arbutus Biopharma Corporation |
Compositions and methods for silencing hepatitis B virus gene expression
|
JP6842410B2
(en)
|
2014-10-03 |
2021-03-17 |
ユニバーシティ オブ マサチューセッツ |
AAV vector identified by a novel high efficiency library
|
US10751317B2
(en)
|
2014-10-08 |
2020-08-25 |
Pacific Northwest Research Institute |
Methods and compositions for increasing the potency of antifungal agents
|
CN107073051B
(en)
|
2014-10-21 |
2021-08-24 |
马萨诸塞大学 |
Recombinant AAV variants and uses thereof
|
WO2016073184A1
(en)
|
2014-11-04 |
2016-05-12 |
Dana Farber Cancer Institute, Inc. |
Compositions and methods for treating multiple myeloma
|
MA41142A
(en)
|
2014-12-12 |
2017-10-17 |
Amgen Inc |
ANTI-SCLEROSTINE ANTIBODIES AND THE USE OF THEM TO TREAT BONE CONDITIONS AS PART OF THE TREATMENT PROTOCOL
|
WO2016100575A1
(en)
|
2014-12-16 |
2016-06-23 |
Board Of Regents Of The University Of Nebraska |
Gene therapy for juvenile batten disease
|
ES2836258T3
(en)
|
2015-03-10 |
2021-06-24 |
Univ Columbia |
Recombinant GLUT1 Adeno-Associated Viral Vector Constructs and Related Methods for Restoring GLUT1 Expression
|
US11285190B2
(en)
|
2015-04-20 |
2022-03-29 |
The Board Of Regents Of The University Of Texas System |
CLEC11a is a bone growth agent
|
WO2016172155A1
(en)
|
2015-04-23 |
2016-10-27 |
University Of Massachusetts |
Modulation of aav vector transgene expression
|
US9976136B2
(en)
|
2015-05-14 |
2018-05-22 |
Longhorn Vaccines And Diagnostics, Llc |
Rapid methods for the extraction of nucleic acids from biological samples
|
WO2016197132A1
(en)
|
2015-06-04 |
2016-12-08 |
Protiva Biotherapeutics Inc. |
Treating hepatitis b virus infection using crispr
|
US10962551B2
(en)
|
2015-06-17 |
2021-03-30 |
The Johns Hopkins University |
TDP-43 in degenerative disease
|
US20180208932A1
(en)
|
2015-07-29 |
2018-07-26 |
Arbutus Biopharma Corporation |
Compositions and methods for silencing hepatitis b virus gene expression
|
US20170056485A1
(en)
|
2015-08-31 |
2017-03-02 |
Sciotec Diagnostic Technologies Gmbh |
Crystallized xylose isomerase in prevention of the development of non-alcoholic fatty liver disease
|
EP3364997B1
(en)
|
2015-10-22 |
2024-01-17 |
University of Massachusetts |
Aspartoacylase gene therapy in the treatment of canavan disease
|
WO2017079746A2
(en)
|
2015-11-07 |
2017-05-11 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
|
ES2919953T3
(en)
|
2016-01-27 |
2022-07-29 |
Oncorus Inc |
Oncolytic viral vectors and uses thereof
|
US10695322B2
(en)
|
2016-01-29 |
2020-06-30 |
The Johns Hopkins University |
Inhibitors of bacterial growth
|
CA3012344A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
US11040025B2
(en)
|
2016-02-17 |
2021-06-22 |
The Johns Hopkins University |
Oxazolidinone for treatment of infections with Mycobacterium tuberculosis
|
US11149060B2
(en)
|
2016-02-19 |
2021-10-19 |
University Of Delaware |
Functionalized nanoparticles for enhanced affinity precipitation of proteins
|
WO2017147215A1
(en)
|
2016-02-22 |
2017-08-31 |
The Methodist Hospital |
Biomimetic proteolipid vesicle compositions and uses thereof
|
WO2017147370A1
(en)
|
2016-02-24 |
2017-08-31 |
The Johns Hopkins University |
Novel antiviral proteins and their uses in therapeutic methods
|
CA3016457A1
(en)
|
2016-03-02 |
2017-09-08 |
The Board Of Regents Of The University Of Texas System |
Sting activating nanovaccine for immunotherapy
|
EP3957331A1
(en)
|
2016-03-03 |
2022-02-23 |
University Of Massachusetts |
Closed-ended linear duplex dna for non-viral gene transfer
|
US10888549B2
(en)
|
2016-03-07 |
2021-01-12 |
The Johns Hopkins University |
Pharmaceutical agents targeting cancer stem cells
|
GB201604124D0
(en)
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
US11203626B2
(en)
|
2016-03-10 |
2021-12-21 |
The Johns Hopkins University |
Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
|
KR102430891B1
(en)
|
2016-03-10 |
2022-08-09 |
더 존스 홉킨스 유니버시티 |
Method for preparing aggregate-free monomeric diphtheria toxin fusion protein and therapeutic use
|
EP3429569A4
(en)
|
2016-03-17 |
2020-02-26 |
The Johns Hopkins University |
Methods for preventing or treating parkinson's disease by the farnesylation of paris
|
EP3436609B1
(en)
|
2016-03-30 |
2022-05-04 |
The Johns Hopkins University |
Olfr90 specificity and methods of detection
|
US11016085B2
(en)
|
2016-04-25 |
2021-05-25 |
The Johns Hopkins University |
ZNT8 assays for drug development and pharmaceutical compositions
|
KR20190009308A
(en)
|
2016-05-21 |
2019-01-28 |
인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) |
Compositions and methods for treating secondary tuberculosis and non-tuberculous mycobacterial infections
|
US11191849B2
(en)
|
2016-06-30 |
2021-12-07 |
Arbutus Biopharma Corporation |
Compositions and methods for delivering messenger RNA
|
MX2019000221A
(en)
|
2016-07-05 |
2020-02-07 |
Univ Massachusetts |
Aav2-mediated gene delivery of sfasl as a neuroprotective therapy in glaucoma.
|
KR102546501B1
(en)
|
2016-07-19 |
2023-06-21 |
유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 |
Oncolytic viruses targeting stat3
|
WO2018035429A1
(en)
|
2016-08-18 |
2018-02-22 |
Wisconsin Alumni Research Foundation |
Peptides that inhibit syndecan-1 activation of vla-4 and igf-1r
|
CA3036218A1
(en)
|
2016-09-16 |
2018-03-22 |
Infectious Disease Research Institute |
Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
US11149275B2
(en)
|
2016-10-10 |
2021-10-19 |
The Johns Hopkins University |
Device and method to treat esophageal disorders
|
US11491114B2
(en)
|
2016-10-12 |
2022-11-08 |
Curioralrx, Llc |
Formulations for enteric delivery of therapeutic agents
|
WO2018071831A1
(en)
|
2016-10-13 |
2018-04-19 |
University Of Massachusetts |
Aav capsid designs
|
KR20190112263A
(en)
|
2016-12-12 |
2019-10-04 |
멀티비르 인코포레이티드 |
Methods and compositions comprising viral gene therapy and immune checkpoint inhibitors for the treatment and prevention of cancer and infectious diseases
|
US10434089B2
(en)
|
2017-01-25 |
2019-10-08 |
The Johns Hopkins University |
Avibactam and carbapenems antibacterial agents
|
CN115845040A
(en)
|
2017-01-27 |
2023-03-28 |
卫理公会医院 |
Core/shell structure platform for immunotherapy
|
CN110505872A
(en)
|
2017-02-12 |
2019-11-26 |
本古里安大学内盖夫研究和发展局 |
Telomerase activation compound for fertility and related application
|
JP2020518275A
(en)
|
2017-05-03 |
2020-06-25 |
バイオマリン ファーマシューティカル インコーポレイテッド |
Improved lentivirus for transduction of hematopoietic stem cells
|
US11680275B2
(en)
|
2017-06-06 |
2023-06-20 |
University Of Massachusetts |
Self-regulating AAV vectors for safe expression of MeCP2 in rett syndrome
|
CN111316099A
(en)
|
2017-07-12 |
2020-06-19 |
约翰霍普金斯大学 |
Proteoliposome-based ZNT8 autoantigen for diagnosis of type 1 diabetes
|
KR20200042904A
(en)
|
2017-07-26 |
2020-04-24 |
온코루스, 인크. |
Oncolytic virus vectors and uses thereof
|
WO2019028469A1
(en)
|
2017-08-04 |
2019-02-07 |
The Methodist Hospital |
Polymer-functionalized mitochondrial compositions and methods of use in cellular transplantation and for altering metabolic phenotype
|
CN111315406A
(en)
|
2017-09-08 |
2020-06-19 |
传染病研究所 |
Liposome formulations comprising saponins and methods of use thereof
|
US20200330541A1
(en)
|
2017-11-16 |
2020-10-22 |
University Of Maine System Board Of Trustees |
Compositions and methods for modulating endothelial cell migration and angiogenesis
|
AU2018378683A1
(en)
|
2017-12-06 |
2020-07-02 |
Memorial Sloan-Kettering Cancer Center |
Globin gene therapy for treating hemoglobinopathies
|
US11246857B2
(en)
|
2017-12-14 |
2022-02-15 |
The Johns Hopkins University |
Anti-fungal inhibitors
|
WO2019118806A1
(en)
|
2017-12-14 |
2019-06-20 |
Solid Biosciences Inc. |
Non-viral production and delivery of genes
|
MX2020007011A
(en)
|
2018-01-05 |
2020-12-03 |
Ottawa Hospital Res Inst |
Modified vaccinia vectors.
|
JP2021518408A
(en)
|
2018-03-19 |
2021-08-02 |
マルチビア インコーポレイテッド |
Methods and Compositions Containing Tumor Suppressor Gene Therapies and CD122 / CD132 Agonists for Cancer Treatment
|
AU2019237514A1
(en)
|
2018-03-23 |
2020-10-08 |
University Of Massachusetts |
Gene therapeutics for treating bone disorders
|
RU2020135495A
(en)
|
2018-03-28 |
2022-04-29 |
Гербалайф Интернэшнл Оф Америка, Инк. |
ACETYLATION OF POLYSACCHARIDES
|
SG11202008206TA
(en)
|
2018-03-30 |
2020-09-29 |
Amgen Inc |
C-terminal antibody variants
|
CA3098448A1
(en)
|
2018-04-27 |
2019-10-31 |
University Of Massachusetts |
Aav capsids identified by in vivo library selection
|
IL278393B2
(en)
|
2018-05-08 |
2023-11-01 |
Univ Rutgers |
Aav-compatible laminin-linker polymerization proteins
|
KR102167755B1
(en)
|
2018-05-23 |
2020-10-19 |
주식회사 큐어바이오 |
Fragmented GRS polypeptide, mutants thereof and use thereof
|
CN113453702A
(en)
|
2018-09-28 |
2021-09-28 |
哈佛大学的校长及成员们 |
Cell reprogramming to reverse senescence and promote tissue and tissue regeneration
|
JP2022501060A
(en)
|
2018-09-28 |
2022-01-06 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
Mutant reverse tetracycline transactivator for gene expression
|
US20220033824A1
(en)
|
2018-11-29 |
2022-02-03 |
University Of Massachusetts |
Modulation of sptlc1 via recombinant adeno-associated vectors
|
AU2020207087A1
(en)
|
2019-01-12 |
2021-08-12 |
The Methodist Hospital |
Self-assembled peptide nanoparticle and use thereof
|
EP3921029A4
(en)
|
2019-02-07 |
2022-12-07 |
Baylor College of Medicine |
Periosteal skeletal stem cells in bone repair
|
EP3927380A1
(en)
|
2019-02-22 |
2021-12-29 |
University of Massachusetts |
Oxr1 gene therapy
|
US11717506B2
(en)
|
2019-05-07 |
2023-08-08 |
The Johns Hopkins University |
Neuroprotective compounds for amyotrophic lateral sclerosis
|
KR20220079857A
(en)
|
2019-09-13 |
2022-06-14 |
루트거스, 더 스테이트 유니버시티 오브 뉴 저지 |
AAV-compatible laminin-linker polymeric protein
|
CA3157063A1
(en)
|
2019-10-10 |
2021-04-15 |
Oncorus, Inc. |
Dual viruses and dual oncolytic viruses and methods of treatment
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
AU2021213735A1
(en)
|
2020-01-30 |
2022-09-22 |
Umoja Biopharma, Inc. |
Bispecific transduction enhancer
|
AU2021248577A1
(en)
|
2020-03-31 |
2022-09-29 |
Sichuan Univeristy |
AAV capsids variants and uses thereof
|
CA3188708A1
(en)
|
2020-08-07 |
2022-02-10 |
Access To Advanced Health Institute |
Purified saponins and chromatographic process for purification of same
|
KR20230117177A
(en)
|
2020-12-03 |
2023-08-07 |
유니버시티 오브 매사추세츠 |
Development of novel gene therapy for progressive ossifying fibrous dysplasia
|
KR20220082558A
(en)
|
2020-12-10 |
2022-06-17 |
재단법인 의약바이오컨버젼스연구단 |
Novel fragmented cysteinyl-tRNA synthetase peptide with immune-enhancing activity and use thereof
|
BR112023014980A2
(en)
|
2021-01-27 |
2023-10-10 |
Umoja Biopharma Inc |
LENTIVIRUS TO GENERATE CELLS EXPRESSING THE ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR
|
WO2023092060A1
(en)
|
2021-11-18 |
2023-05-25 |
Cornell University |
Microrna-dependent mrna switches for tissue-specific mrna-based therapies
|
GB2614309A
(en)
|
2021-12-24 |
2023-07-05 |
Stratosvir Ltd |
Improved vaccinia virus vectors
|
WO2023144393A1
(en)
|
2022-01-28 |
2023-08-03 |
Fundació Centre De Regulació Genòmica |
Therapeutic cytokines and methods
|
WO2023144792A1
(en)
|
2022-01-31 |
2023-08-03 |
Genevant Sciences Gmbh |
Poly(alkyloxazoline)-lipid conjugates and lipid particles containing same
|
WO2023144798A1
(en)
|
2022-01-31 |
2023-08-03 |
Genevant Sciences Gmbh |
Ionizable cationic lipids for lipid nanoparticles
|
WO2023196851A1
(en)
|
2022-04-06 |
2023-10-12 |
President And Fellows Of Harvard College |
Reversing aging of the central nervous system
|
WO2023215481A1
(en)
|
2022-05-05 |
2023-11-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
INTERFERING RNA THERAPY FOR PLN-R14del CARDIOMYOPATHY
|
WO2023225569A1
(en)
|
2022-05-17 |
2023-11-23 |
Umoja Biopharma, Inc. |
Manufacturing viral particles
|